SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: VLAD who wrote (17561)1/8/1999 5:02:00 PM
From: Mkilloran  Read Replies (2) | Respond to of 23519
 
Vlad....The Viagra news is starting to draw investors to other alternatives away from PFE.

Zona is the next oral med that is inline to get FDA approval. Investors are moving money into Zona now.

Once the Vivus partner is announced for the USA the same will happen to Vivus.

It doesn't matter if you have a safe and effective product (MUSE) if you have no marketing/sales force.



To: VLAD who wrote (17561)1/8/1999 6:20:00 PM
From: Edderd  Read Replies (2) | Respond to of 23519
 
VLAD
You are missing the point Vasomax is oral and Vivus isn't. That's why noone want's to risk money on it. They think Vasomax might be effective and the next great oral drug. Find a good time to short it.
Ed


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News